Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports.

[1]  Weina Lu,et al.  Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Who Underwent Surgery for Pancreatic Carcinoma: A Case Report , 2022, Frontiers in Surgery.

[2]  R. D. de Boer,et al.  Kidney and heart failure outcomes associated with SGLT2 inhibitor use , 2022, Nature Reviews Nephrology.

[3]  E. Pathrose,et al.  “The Bitter Truth of Sugar”—Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series , 2021, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[4]  A. Ashmeg,et al.  Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review , 2021, Case reports in medicine.

[5]  K. Yasuda,et al.  Multicentre prospective observational study of sodium-glucose cotransporter-2 inhibitor-associated postoperative ketoacidosis: the SAPKA study protocol , 2021, BMJ Open.

[6]  F. Giorgino,et al.  SGLT2 inhibitors as cardio-renal protective agents. , 2021, Metabolism: clinical and experimental.

[7]  J. Gotts,et al.  Euglycemic diabetic ketoacidosis following major vascular surgery is a new item on the differential for postoperative acidosis , 2021, Journal of vascular surgery cases and innovative techniques.

[8]  P. Chahar,et al.  Perioperative challenges in management of diabetic patients undergoing non-cardiac surgery , 2021, World journal of diabetes.

[9]  S. Vadi,et al.  Perioperative Implication of Sodium-glucose Cotransporter-2 Inhibitor in a Patient Following Major Surgery , 2021, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[10]  E. Tschernko,et al.  Euglycemic Diabetic Ketoacidosis After Cardiac Surgery in a Patient Treated With Empagliflozin for Type 2 Diabetes Mellitus: A Case Report. , 2021, Journal of cardiothoracic and vascular anesthesia.

[11]  Z. Yousaf,et al.  SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort , 2021, Scientific Reports.

[12]  P. Colman,et al.  Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: single centre experience and recommendations. , 2021, British journal of anaesthesia.

[13]  Douglas R. Ewing,et al.  Two cases of euglycemic diabetic ketoacidosis after bariatric surgery associated with sodium-glucose cotransporter-2 inhibitor use , 2021, Obesity Surgery.

[14]  Y. Mehta,et al.  Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery. , 2021, Diabetes & metabolic syndrome.

[15]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[16]  F. B. Arantes,et al.  Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery. , 2021, Journal of clinical anesthesia.

[17]  J. Gamble,et al.  Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews , 2021, Therapeutic advances in drug safety.

[18]  J. Karam,et al.  A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery , 2020, AACE clinical case reports.

[19]  G. Fuhrman,et al.  Euglycemic Diabetic Ketoacidosis in the Surgical Patient. , 2020, The American surgeon.

[20]  Sheri M. Berg,et al.  Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier’s gangrene: A case report , 2020, International journal of surgery case reports.

[21]  N. Cribben,et al.  Is there a role for cough suppression techniques in the COVID‐19 era? , 2020, Anaesthesia.

[22]  G. Mancini,et al.  Euglycemic Diabetic Ketoacidosis Associated With Use of SGLT2 Inhibitor After Laparoscopic Roux-en-Y Gastric Bypass , 2020, The American surgeon.

[23]  M. Nishi,et al.  Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report , 2020, Journal of diabetes investigation.

[24]  A. Papagianni,et al.  Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review , 2020, BMC Nephrology.

[25]  Katherine M Wang,et al.  SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report , 2020, Kidney medicine.

[26]  W. Freeman,et al.  Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and “Sweet Pee Encephalopathy” in Perioperative Hospital Management , 2020, The Neurohospitalist.

[27]  A. Rozycki,et al.  442: Diagnosis and Management of SGLT-2 Inhibitor-Induced Euglycemic DKA After Cardiac Surgery , 2020 .

[28]  E. Meyer,et al.  Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. , 2019, British journal of anaesthesia.

[29]  Sachin Gupta,et al.  Euglycemic diabetic ketoacidosis in association with dapagliflozin use after gastric sleeve surgery in a patient with type II diabetes mellitus , 2019, Clinical case reports.

[30]  T. Kitamura,et al.  Ketoacidosis related to sodium glucose cotransporter 2 inhibitors after emergency coronary surgery. , 2019, Interactive cardiovascular and thoracic surgery.

[31]  D. Theodore,et al.  Euglycemic ketoacidosis in a postoperative deformity correction spine surgery patient: a case report , 2018, Journal of Emergency and Critical Care Medicine.

[32]  C. van Niekerk,et al.  Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin , 2018, BMJ Case Reports.

[33]  M. Tamilia,et al.  Euglycemic diabetic ketoacidosis associated with the use of a sodium–glucose cotransporter-2 inhibitor , 2018, Canadian Medical Association Journal.

[34]  Marilyn Schallom,et al.  Discrepancies in measuring bladder volumes with bedside ultrasound and bladder scanning in the intensive care unit: A pilot study , 2018, Journal of the Intensive Care Society.

[35]  P. A. Crawford,et al.  Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin , 2018, Diabetes, obesity & metabolism.

[36]  E. Meyer,et al.  SGLT2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications , 2018, Diabetes Care.

[37]  A. Chau,et al.  Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery , 2018, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[38]  E. Keely,et al.  Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis. , 2017, Canadian journal of diabetes.

[39]  J. Greenfield,et al.  Euglycaemic diabetic ketoacidosis in patients using sodium‐glucose co‐transporter 2 inhibitors , 2017, Internal medicine journal.

[40]  A. Avogaro,et al.  SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System , 2017, Diabetologia.

[41]  J. Buse,et al.  Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions , 2017, Diabetes Care.

[42]  H. Tilg,et al.  Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes , 2016, Diabetes.

[43]  E. Keely,et al.  SGLT2-Inhibitor Use Associated with Euglycemic Ketoacidosis: A Case Series , 2016 .

[44]  J. Hallet,et al.  Euglycaemic ketoacidosis in a postoperative Whipple patient using canaglifozin , 2016, BMJ Case Reports.

[45]  D. Topliss,et al.  Lessons from the bedside: ketoacidosis and SGLT2 inhibitors , 2016, The Medical journal of Australia.

[46]  R. Aggarwal,et al.  Diabetic Ketoacidosis Following Bariatric Surgery in Patients With Type 2 Diabetes , 2016, Diabetes Care.

[47]  R. Malik,et al.  Perioperative management of diabetes in elective patients: a region-wide audit. , 2016, British journal of anaesthesia.

[48]  F. Bonanni,et al.  Normoglycemic ketoacidosis in a postoperative gastric bypass patient taking canagliflozin. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[49]  M. H. Nathanson,et al.  Peri‐operative management of the surgical patient with diabetes 2015 , 2015, Anaesthesia.

[50]  G. Meininger,et al.  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program , 2015, Diabetes Care.

[51]  I. Hirsch,et al.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.

[52]  V. Vallon.  The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. , 2015, Annual review of medicine.

[53]  D. Matthews,et al.  Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes , 2013, Annals of Internal Medicine.

[54]  K. Dhatariya,et al.  NHS Diabetes guideline for the perioperative management of the adult patient with diabetes * , 2012, Diabetic medicine : a journal of the British Diabetic Association.